NCT04051606View on ClinicalTrials.gov

Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

March 20, 2024

Study Completion Date

March 20, 2024

Conditions
Recurrent Glioblastoma
Interventions
DRUG

Regorafenib

Regorafenib is a monotherapy during the study, oral administration at 160 mg once daily will be administered for 3 weeks on /1 week off.

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT04051606 - Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter